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We report a case of lymphadenitis caused by Mycobacte-
rium orygis in an immunocompetent person in Stony Brook, 
New York, USA. Initial real-time PCR assay failed to provide 
a final subspecies identification within the M. tuberculosis 
complex, but whole-genome sequencing characterized the 
isolate as M. orygis.
Genomic analysis has previously shown that the Myco-bacterium tuberculosis (MTB) complex comprises >8 
distinct subgroups: M. tuberculosis, M. africanum, M. ca-
nettii, M. bovis, M. caprae, M. pinnipedii, M. microti, and 
M. mungi (1). M. orygis was first characterized in Africa 
and South Asia in 2012 based on examination of 22 isolates 
selected for the similarity of their IS6110 restriction frag-
ment length polymorphism patterns to previously described 
oryx bacilli (2). Eleven of these isolates were from animals 
(a cow, a rhesus monkey, and types of antelope including 
oryx), and 11 were from humans (9 from South Asia). On 
the basis of single-nucleotide polymorphism (SNP) and re-
gion of difference (RD) analysis, van Ingen et al. concluded 
that these mycobacteria belonged to a phylogenetically dis-
tinct lineage of the clonal MTB complex (2). M. orygis is 
also distinguished by a mutation in gene Rv2042c (2) and a 
G1113A mutation in the gyrB gene (3). 
We report a case of lymphadenitis caused by M. orygis 
in an immunocompetent person in Stony Brook, New York, 
USA. During July 2015, we diagnosed pneumonia in the 
upper lobe of the right lung in a woman, 71 years of age, 
who had a remote history of lymphoma. The condition was 
characterized by enlarged lymph nodes. The patient was 
born in Pakistan, moved to India at age 1, and emigrated 
to the United States ≈25 years before onset; her preimmi-
gration TB skin test was <5 mm (bacillus Calmette-Guérin 
vaccinated), and chest radiograph results were negative. 
She drank unpasteurized milk while living in India. 
We completed positron emission and computed 
tomography scans by using intravenous F-18 fluoro-2- 
deoxyglucose that detected hypermetabolic foci in the right 
axilla, subpectoral, subcarinal, and para hilar regions. Quan-
tiFERON-TB Gold in-tube system (Quest Diagnostics, Inc., 
Lyndhurst, NJ, USA) test result was positive (TB antigen 
minus nil value 3.58 IU/Ml, mitogen minus nil value 8.5 
IU/mL). Three induced sputum samples for acid-fast bacilli 
smear and cultures were negative. Because of the patient’s 
history of lymphoma, we biopsied the subpectoral lymph 
node. Histopathology revealed diffuse large caseating 
granulomas with extensive central necrosis, small lympho-
cytes, plasma cells, and histiocytes. Grocott’s Methenamine 
Silver Stain (Ventana Medical Systems, Inc. Tucson, AZ, 
USA), and acid-fast bacilli stains did not detect organisms. 
Bacterial and fungal cultures were negative. 
Mycobacterium Growth Indicator Tube (MGIT) sys-
tem turned positive on day 29, and the isolate was identified 
as MTB complex by probe hybridization (Hologic, Inc. San 
Diego, CA, USA). Further testing at the New York State 
Department of Health with real-time PCR using primers/
probes specific for 4 MTB regions of difference yielded an 
inconclusive pattern (4). Results were positive for RD1 and 
RD4, but negative for RD9 and RD12; subspecies identifi-
cation was initially reported as “inconclusive” because this 
pattern did not match the signature patterns used to deter-
mine MTB complex species with this assay. 
We performed a whole-genome sequencing assay that 
confirmed the absence of RD9 and RD12 and identified 
the isolate as M. orygis, as reported by Shea et al (5). This 
isolate belonged to Spogliotype International Type 587, 
contained the specific gyrB SNP at position 1113 (3), and 
lacked resistance-associated mutations, suggesting suscep-
tibility to all tested current antituberculosis agents. The pa-
tient received first-line, 4-drug therapy.
M. orygis infections in humans have been rarely re-
ported. In Australia, of 1,763 case-patients diagnosed with 
MTB complex infection, 8 causative pathogens were iden-
tified as M. orygis; all of the patients were born in India (6). 
In New Zealand, Dawson et al. used advanced molecular 
techniques to demonstrate a transmission of M. orygis from 
a human, who emigrated from India, to a cow (7). 
M. orygis infection may be underreported in the lit-
erature because cases may be identified as MTB complex 
or misidentified as M. africanum or M. bovis (8). Through 
whole-genome sequencing, the New York State Depart-
ment of Health identified 8 additional cases of M. orygis 
of 6,322 MTB complex isolates from New York tested (3 
pulmonary, 2 lymph node, and 2 abscess samples) that were 
received during 2005–2016 but were initially misidentified 
(data not shown). All patients were from India, Pakistan, or 
Nepal and had moved to the United States. SNP analysis in-
dicated that the M. orygis isolates were genetically similar, 
but all were distant from other members of the MTB com-
plex (Figure) and contained the G1113A mutation in gyrB. 
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The number of SNPs separating the 8 M. orygis isolates 
was 106–323, which excludes their belonging to an epide-
miologic transmission cluster (9) and strongly suggests that 
the infections were independently acquired.
We found no previous reports of M. orygis originating 
in the Americas; the most notable epidemiologic risk factor 
in this patient was prior residency in India, where M. orygis 
was found in a variety of animals (10). Because all organ-
isms in the MTB complex have a distinct host preference, 
it is possible that M. orygis is mostly present in animals and 
few cases occur in humans, similar to M. bovis. This case 
demonstrates the value of molecular methodologies such 
as whole-genome sequencing for providing more detailed 
insight into the clinical and epidemiologic aspects of the 
MTB complex.
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polymorphism (SNP) tree of 8 
Mycobacterium orygis and 1 M. 
caprae isolates obtained from 
patients in New York, USA. 
Alignment of 5,242 total SNP 
positions was calculated by 
using PhyML version 20111216 
(http://www.atgc-montpellier.fr/
phyml/) general time reversible 
plus gamma model under 
8 categories with best of 
nearest-neighbor interchange, 
subtree pruning, and regrafting 
with 5 random starting trees. 
Included in the tree are M. 
tuberculosis H37Rv (GenBank 
accession no. NC_000962), 
M. orygis (accession no. 
APKD01000001.1), M. bovis 
(accession no. NC_002945.3), 
M. africanum (accession no. 
NC_015758.1), and M. microti (ATCC 35782) reference sequences. SNP analysis of the isolate from the patient described in this study (LN 
2016) with 7 other M. orygis strains identified at the New York State Department of Health showed differences ranging from 170 (closest) to 
323 (farthest) SNPs. By comparison, the closest non–M. orygis M. tuberculosis complex species is M. microti (1,880 SNPs). All M. orygis 
strains are grouped with 100% bootstrap support. Scale bar indicates average number of substitutions per site. Specimen sources: Resp, 
respiratory; Absc, abcess; LN, lymph node (BioProject ID PRJNA389109 containing BioSample accessions SAMN07190143–50).
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Ross River virus (RRV), spread by Aedes and Culex mos-
quitoes, is the most commonly transmitted arbovirus in Aus-
tralia. A serosurvey of blood donors in French Polynesia 
during 2011–2013 suggested that RRV circulated without 
being detected. We report RRV circulation in French Poly-
nesia based on further screening of blood samples collect-
ed during 2014–2015.
Ross River virus (RRV), an alphavirus of the family Togaviridae, is an arbovirus transmitted by Aedes and 
Culex mosquito species (1). Symptoms of RRV infections 
mainly consist of fever, arthralgia, and rash. RRV was first 
isolated in North Queensland in 1959 and has become the 
most common arboviral disease in Australia (2). RRV out-
breaks were reported during 1979–1980 in Pacific Island 
countries and territories (PICTs) including Fiji, Cook Is-
lands, American Samoa, and New Caledonia (1). 
In French Polynesia (FP), a territory of the Pacific 
region with ≈270,000 inhabitants, dengue virus (DENV) 
was the only arbovirus detected until identification of the 
Zika virus (ZIKV), then chikungunya virus (CHIKV), 
causing outbreaks during 2013–2014 and 2014–2015, re-
spectively (3). Although RRV infections have never been 
reported in FP, a serosurvey of blood donors during 2011–
2013 suggested that RRV has circulated without being de-
tected (4). In this study, we report additional evidence of 
RRV circulation in FP based on further screening of blood 
samples collected during 2014–2015 and previously used 
for a ZIKV serosurvey (5).
We tested 3 groups of participants randomly sampled in 
FP for the presence of anti-RRV IgG by using recombinant an-
tigen-based indirect ELISA (patent no.WO2012076715A1) 
and microsphere multiplex immunoassay (patent no. 
WO2013083847A2) (4,5). The first group consisted of 196 
participants recruited during February–March 2014 in 8 of 
the most inhabited islands of the 5 FP archipelagos (archi-
pelagos listed in parentheses): Tahiti and Moorea (Society), 
Rangiroa and Makemo (Tuamotu), Nuku Hiva and Hiva 
Oa (Marquesas), Rurutu (Austral), and Rikitea (Gambier). 
The second group included 700 participants recruited dur-
ing September–November 2015 on the 2 most inhabited is-
lands of FP: Tahiti and Moorea. The third group consisted 
of 476 schoolchildren recruited during May–June 2014 on 
Tahiti. The Ethics Committee of French Polynesia approved 
recruitment of participants and processing of blood samples 
(approval no. 60/CEPF-06/27/2013). We analyzed serop-
revalence data by using the Fisher exact test, and considered 
p values <0.05 as statistically significant.
RRV seropositivity rates among participants sampled in 
the 5 archipelagos in 2014 ranged from 16% to 49% (aver-
age 35%), and were significantly different between the So-
ciety and Marquesas (p = 0.036), Tuamotu and Marquesas 
(p = 0.001), and Tuamotu and Austral-Gambier (p = 0.002) 
Islands (Table). In the Society Islands, screening of additional 
participants in 2015 did not lead to a significant difference 
in RRV seroprevalence (18%) compared with the 1 observed 
in the participants recruited in 2014 (27%) (p = 0.125). In 
contrast, RRV seroprevalence among schoolchildren (1%) 
was significantly lower than in the general population from 
the Society Islands, during both 2014 and 2015 (p<0.0001). 
We compared 2 groups in the general population in 2014 
and 2015. Rates of participants whose samples were RRV– 
seropositive and who were born or arrived in FP before 
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